{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-238989","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.398901+00:00","generated_at":"2026-05-17T03:52:10.822987+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Fate Therapeutics appoints Kamal Adawi as CFO, board resignations reduce size from 10 to 8","bullets":["Kamal Adawi appointed CFO effective Oct 20, 2025; base salary $495k, target bonus 40%.","Adawi receives 375k stock option and 75k RSUs as inducement equity grants, vesting over 4 years.","Board members John Mendlein and Neelufar Mozaffarian resigned voluntarily effective Oct 13, 2025.","Board size decreased from 10 to 8 directors following resignations.","CFO role focused on supporting registrational path for FT819 in SLE and pipeline progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-238989","json":"https://secwatch.observer/filing/0001193125-25-238989.json","markdown":"https://secwatch.observer/filing/0001193125-25-238989.md","text":"https://secwatch.observer/filing/0001193125-25-238989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525238989/0001193125-25-238989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525238989/fate-20251010.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:52:10.822987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}